Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.533
+0.005 (0.98%)
At close: Feb 21, 2025, 4:00 PM
0.540
+0.007 (1.24%)
After-hours: Feb 21, 2025, 7:13 PM EST
Mersana Therapeutics Revenue
Mersana Therapeutics had revenue of $12.60M in the quarter ending September 30, 2024, with 63.65% growth. This brings the company's revenue in the last twelve months to $34.84M, down -14.70% year-over-year. In the year 2023, Mersana Therapeutics had annual revenue of $36.86M with 38.65% growth.
Revenue (ttm)
$34.84M
Revenue Growth
-14.70%
P/S Ratio
1.86
Revenue / Employee
$283,228
Employees
123
Market Cap
65.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.86M | 10.27M | 38.65% |
Dec 31, 2022 | 26.58M | 26.54M | 61,716.28% |
Dec 31, 2021 | 43.00K | -785.00K | -94.81% |
Dec 31, 2020 | 828.00K | -41.30M | -98.03% |
Dec 31, 2019 | 42.12M | 31.53M | 297.61% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MRSN News
- 15 days ago - Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 6 weeks ago - Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? - Benzinga
- 6 weeks ago - Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) - GlobeNewsWire
- 6 weeks ago - Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer - GlobeNewsWire
- 2 months ago - Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable - Seeking Alpha
- 3 months ago - Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewsWire